Oncodesign Precision Medicine Overview
Pro stress-test →Oncodesign Precision Medicine is a biopharmaceutical company specializing in precision medicine with a pipeline including OPM-101 (a RIPK2 inhibitor for inflammatory bowel disease and immuno-oncology), OPM-102 for cancer treatment, and OPM-201 (a LRRK2 inhibitor for Parkinson's disease). The company aims to provide effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
Strategic Profile
Pro stress-test →The company leverages innovative technologies including OncoSNIPER for therapeutic target selection using AI, Nanocyclix® for designing macrocyclic kinase inhibitors, and Promethe for developing radiolabeled molecules for radiotherapy. OPM-101 has advanced to Phase 1b/2a clinical trials (REVERT study) in advanced melanoma patients resistant to anti-PD-1 therapy.
Competitive Landscape
Pro stress-test →OPM competes in the immuno-oncology space where anti-PD-1 checkpoint inhibitors dominate but face significant resistance and toxicity issues. OPM-101's RIPK2 inhibitor approach targets these limitations by potentially increasing response rates and reducing immune-related side effects of existing therapies. The company faces competition from larger pharma and specialized immuno-oncology biotech firms.
Industry Context
Oncodesign Precision Medicine operates in Biopharmaceutical/Precision Oncology.
Key facts
Founded: 1995 · Headquarters: Dijon, France · Revenue: $225K (trailing 12M) · Market cap: $15.7M